摘要
目的分析双歧杆菌乳杆菌三联活菌片辅助护肝药物治疗肝硬化合并自发性腹膜炎患者的效果。方法选取2016年7月~2017年11月我院收治的100例肝硬化合并自发性腹膜炎患者作为研究对象,随机将其分为观察组与对照组,每组各50例。对照组患者采用常规保肝药物治疗,观察组患者在对照组基础上加入双歧杆菌乳杆菌三联活菌片进行治疗。观察两组患者的临床疗效、临床症状缓解时间、治疗前后免疫功能变化及治疗结束半年后随访的自发性腹膜炎复发率。结果观察组患者的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组患者的高热、腹部压痛及反跳痛缓解时间均显著短于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的T淋巴细胞亚群CD4+/CD8+比值高于治疗前,差异有统计学意义(P<0.05),观察组患者治疗后的T淋巴细胞亚群CD4+/CD8+比值显著高于对照组,差异有统计学意义(P<0.05);治疗结束半年后随访,观察组患者的自发性腹膜炎复发率(22.0%)显著低于对照组(46.0%),差异有统计学意义(P<0.05)。结论双歧杆菌乳杆菌三联活菌片辅助护肝药物在肝硬化合并自发性腹膜炎患者临床治疗中具有较好的应用效果,能够有效缓解患者的临床症状,提高患者的免疫功能,从而降低复发率,值得在临床中推广使用。
Objective To analyze the effect of Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets in the treatment of cirrhotic patients with spontaneous peritonitis. Methods From July 2016 to November 2017, a total of 100 patients with cirrhosis complicated with spontaneous peritonitis were selected as objects and randomly divided into observation group and control group, with 50 cases in each group. The patients in the control group were treated with conventional hepatoprotective drugs, while patients in the observation group were treated with Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets on the basis of the control group. The clinical efficacy, clinical symptom remission time, immune function before and after treatment, and the recurrence rate of spontaneous peritonitis half a year follow-up after treatment of the two groups were observed. Results The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant（P〈0.05）. The remission time of hyperthermia, abdominal pressure pain, and rebound pain in the observation group were significantly shorter than those in the control group, and the differences were statistically significant（P〈0.05）. The ratio of CD4＋/CD8＋T-lymphocyte subsets after treatment in the observation group was higher than that before treatment, and the difference was statistically significant（P〈0.05）. The ratio of CD4＋/CD8＋of T-lymphocyte subsets after treatment in the observation group was significantly higher than that in the control group, and the difference was statistically significant（P〈0.05）. The recurrence rate of spontaneous peritonitis after half a year follow-up in the observation group（22.0%） was significantly lower than that in the control group（46.0%）, and the difference was statistically significant（P〈0.05）. Conclusion Bifidobacterium Lactobacillus Triple Viable Bacteria Tablets are effective in the clinical treatment of patients with cirrhosis and spontaneous peritonitis, which can effectively relieve the clinical symptoms and improve the immune function of patients with liver cirrhosis and spontaneous peritonitis, thereby reducing the recurrence rate, and they are worthy of clinical promotion and application.
作者
林任萍
LIN Ren-ping(Department of Gastroenterology,the Second People＇s Hospital in Jiangmen City,Guangdong Province,Jiangmen 529100,China)
出处
《中国当代医药》
2018年第21期95-97,101,共4页
China Modern Medicine
关键词
双歧杆菌乳杆菌三联活菌片
护肝药物
肝硬化
自发性腹膜炎
Bifidobaeterium Laetobaeillus Triple Viable Bacteria Tablets
Liver protection drugs
Liver cirrhosis
Spontaneous peritonitis
